Comparison of different severe obesity definitions in predicting future cardiometabolic risk in a longitudinal cohort of children.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
15 06 2022
Historique:
entrez: 15 6 2022
pubmed: 16 6 2022
medline: 18 6 2022
Statut: epublish

Résumé

Severe obesity (SO) prevalence varies between reference curve-based definitions (WHO: ≥99th percentile, Centers for Disease Control and Prevention (CDC): >1.2×95th percentile). Whether SO definitions differentially predict cardiometabolic disease risk is critical for proper clinical care and management but is unknown. Prospective cohort study SETTING: SO definitions were applied at baseline (2005-2008, M Respondents were youth who had at least one biological parent with obesity. Unfavourable cardiometabolic levels of fasting blood glucose (≥6.1 mmol/L), insulin resistance (HOMA-IR index ≥2.0), high-density lipoprotein <1.03 mmol/L, low-density lipoprotein ≥2.6 mmol/L and triglycerides Area under the receiver operating characteristic curve (AUC) and McFadden psuedo R Baseline SO prevalence differed (WHO: 18%, CDC: 6.7%). AUCs ranged from 0.52 to 0.77, with fair agreement (kappa=37%-55%). WHO-SO AUCs for detecting unfavourable HOMA-IR (AUC>0.67) and high-density lipoprotein (AUC>0.59) at F1 were statistically superior than CDC-SO (AUC>0.59 and 0.53, respectively; p<0.05). Only HOMA-IR and the presence of more than three risk factors had acceptable model fit. WHO-SO was not more predictive than WHO-obesity, but CDC-SO was statistically inferior to CDC-obesity. WHO-SO is statistically superior at predicting cardiometabolic risk than CDC-SO. However, as most AUCs were generally uninformative, and obesity definitions were the same if not better than SO, the improvement may not be clinically meaningful.

Identifiants

pubmed: 35705336
pii: bmjopen-2021-058857
doi: 10.1136/bmjopen-2021-058857
pmc: PMC9204411
doi:

Substances chimiques

Blood Glucose 0
Lipoproteins, HDL 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e058857

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Pediatr. 2007 Jan;150(1):12-17.e2
pubmed: 17188605
Acta Diabetol. 2016 Apr;53(2):251-60
pubmed: 26070771
Int J Epidemiol. 2012 Dec;41(6):1533-44
pubmed: 21785124
Radiology. 1983 Sep;148(3):839-43
pubmed: 6878708
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Pediatrics. 2011 Dec;128 Suppl 5:S213-56
pubmed: 22084329
Clin Chem Lab Med. 1999 Oct;37(10):949-58
pubmed: 10616748
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
PLoS One. 2015 Mar 04;10(3):e0118432
pubmed: 25738806
Pediatrics. 2012 Dec;130(6):1136-40
pubmed: 23129082
Child Obes. 2016 Feb;12(1):12-9
pubmed: 26785314
Stat Med. 1992 Jul;11(10):1305-19
pubmed: 1518992
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76
pubmed: 15286277
Circulation. 2004 Sep 28;110(13):1832-8
pubmed: 15381642
Am J Clin Nutr. 2009 Nov;90(5):1314-20
pubmed: 19776142
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Semin Nucl Med. 1978 Oct;8(4):283-98
pubmed: 112681
Paediatr Child Health. 2010 Feb;15(2):77-83
pubmed: 21286295
Acad Radiol. 1997 Jan;4(1):49-58
pubmed: 9040870
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Child Obes. 2014 Aug;10(4):283-4
pubmed: 24983291
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Clin Chem. 1998 Aug;44(8 Pt 1):1629-40
pubmed: 9702949
PLoS One. 2013 Dec 27;8(12):e83793
pubmed: 24386280
J Pediatr. 2010 Jul;157(1):26-31.e2
pubmed: 20303506
Circulation. 2013 Oct 8;128(15):1689-712
pubmed: 24016455
Int J Obes (Lond). 2014 Sep;38 Suppl 2:S39-47
pubmed: 25376219
Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7
pubmed: 12912790
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Pediatrics. 2007 Dec;120 Suppl 4:S164-92
pubmed: 18055651
Rev Paul Pediatr. 2016 Jun;34(2):234-42
pubmed: 26559605

Auteurs

Lisa Kakinami (L)

PERFORM Centre, Concordia University, Montreal, Québec, Canada lisa.kakinami@concordia.ca.
Department of Mathematics and Statistics, Concordia University, Montreal, Québec, Canada.

Anna Smyrnova (A)

Department of Mathematics and Statistics, Concordia University, Montreal, Québec, Canada.

Gilles Paradis (G)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.

Angelo Tremblay (A)

Département de kinésiologie, Université Laval, Quebec City, Quebec, Canada.

Melanie Henderson (M)

Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada.
Research Center of CHU Sainte Justine, Université de Montréal, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH